

Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study

Rachel A. Charlton, PhD^a, Julia M. Snowball, BSc^a, Alison L. Nightingale, PhD^a, and Kourtney J. Davis, PhD^b Bath, UK; and Wavre, Belgium

What is already known about this topic? Little is known about the safety of many inhaled corticosteroids when used during pregnancy, and with the exception of the Swedish Medical Birth Register study of budesonide, there is limited data from studies in humans.

What does the article add to our knowledge? This study found no increase in the overall risk of major congenital malformations after exposure to fluticasone propionate during the first trimester of pregnancy compared with exposure to nonfluticasone propionate inhaled corticosteroids.

How does the study impact current management guidelines? This study supports the findings of studies evaluating the safety of other inhaled corticosteroids and provides reassurance to women and clinicians that fluticasone propionate is not a major teratogen.

BACKGROUND: Asthma is commonly treated during pregnancy, yet data on the safety of asthma medicines used during pregnancy are sparse.

OBJECTIVE: The objective of this study was to evaluate the safety of the inhaled corticosteroid (ICS) fluticasone propionate (FP), alone and in fixed-dose combination with salmeterol (FSC) in terms of the risk of all major congenital malformations (MCMs), compared with all other non-FP ICS.

METHODS: Women with asthma who had a pregnancy between January 1, 2000, and December 31, 2010, were identified in the United Kingdom's Clinical Practice Research Datalink. Exposure to asthma medicines during the first trimester of pregnancy was based on issued prescriptions. The mothers' and infants' medical records were linked where possible, and pregnancy outcomes with an MCM diagnosed by age 1 year were identified based on medical codes in the mother's and infant's medical records, including those MCMs prenatally diagnosed that ended in an induced pregnancy termination. The absolute

and relative risks of an MCM after different ICS exposures, stratified by the asthma treatment intensity level, were calculated.

RESULTS: A total of 14,654 mother-infant pairs were identified, of which 6,174 received an ICS prescription during the first trimester, in addition to 13 first trimester ICS exposed pregnancies that ended in an induced termination after a prenatal MCM diagnosis. In total, 5,362 pregnancies were eligible for the primary analysis at age 1 year. The absolute risk of an MCM after any first trimester FP exposure was 2.4% (CI₉₅ 0.8-4.1) and 2.7% (CI₉₅ 1.8-3.6) for the "moderate" and "considerable/severe" asthma treatment intensity levels, respectively. The adjusted odds ratios when compared with non-FP ICS were 1.1 (CI₉₅ 0.5-2.3) and 1.2 (CI₉₅ 0.7-2.0) for the "moderate" and "considerable/severe" intensity levels; risks for any FP and for FSC did not differ substantially.

CONCLUSION: No increase in the overall risk of MCMs was identified after first trimester FP exposure compared with non-FP ICS. © 2015 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2015;3:772-9)

Key words: Pregnancy; Asthma; Anti-asthmatic agents; Congenital abnormalities; Electronic medical records; Teratogens

Asthma affects between 3% and 14% of pregnancies.¹⁻⁵ Maternal asthma, and in particular poorly controlled asthma, is associated with a number of adverse perinatal outcomes including preterm delivery and pre-eclampsia.^{6,7} Consequently, asthma treatment guidelines highlight the importance of maintaining good asthma control during pregnancy, with inhaled corticosteroids (ICS) recommended as first-line controller therapies.⁸ Pregnant women, however, are typically excluded from randomized controlled trials, and at present there is little knowledge about the safety of many asthma medicines when used during pregnancy. As a result, all ICS with the exception of

^aDepartment of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, United Kingdom

^bGlaxoSmithKline R&D, Worldwide Epidemiology, Wavre, Belgium

This study was funded by GlaxoSmithKline (WEUSRTP4850).

Conflicts of interest: R. A. Charlton has received research support from GlaxoSmithKline (Study number WEUSRTP4850) and Chiesi; and has stock/stock options in GlaxoSmithKline. J. M. Snowball and A. L. Nightingale have received research support from GlaxoSmithKline (Study number WEUSRTP4850) and Chiesi. K. J. Davis is employed by and owns stock/stock options in GlaxoSmithKline.

Received for publication October 17, 2014; revised May 6, 2015; accepted for publication May 12, 2015.

Available online June 25, 2015.

Corresponding author: Rachel A. Charlton, PhD, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom. E-mail: r.a.charlton@bath.ac.uk.

2213-2198

© 2015 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaip.2015.05.008>

Abbreviations used

BDP- Beclometasone dipropionate
CPRD- Clinical Practice Research Datalink
FP- Fluticasone propionate
FSC- Fluticasone propionate in fixed dose combination with salmeterol (Seretide)
GP- General Practitioner
GPRD- General Practice Research Database
ICS- Inhaled corticosteroid
LABA- Long-acting β_2 -agonist
MCM- Major congenital malformations

budesonide, which is category B based on data from the Swedish Medical Birth Register, have a Food and Drug Administration pregnancy category C, indicative of the fact that there are no adequate and well-controlled studies in humans.

Fluticasone propionate (FP) is an ICS used for the treatment of asthma, as monotherapy and in fixed-dose combination with the long-acting β_2 -agonist (LABA) salmeterol. Owing to small numbers of pregnancy exposures in the past, little is known about its safety when used during pregnancy. A recent feasibility study,⁵ however, demonstrated that there are now sufficient numbers of first trimester exposed pregnancies in the Clinical Practice Research Datalink (CPRD) to allow the overall risk of major congenital malformations (MCMs) to be evaluated. This study aimed to evaluate the safety profile of FP, in terms of the risk of MCMs, compared with all other non-FP ICS exposures, while taking into account potential confounders.

METHODS

The CPRD, previously the General Practice Research Database, contains anonymized patient medical and prescribing records from UK primary care.⁹ Within the CPRD, it is possible to link a mother's medical record to her infant's, which enables the evaluation of data on both maternal drug exposure and pregnancy outcomes.¹⁰⁻¹² Data are entered as Read clinical codes and general practitioners (GPs) can record additional noncoded free text comments, which researchers can request from the database provider. This protocol was approved by the CPRD Independent Scientific Advisory Committee, and there is a single Multi-Centre Ethics approval for observational studies using CPRD data.

Women with a pregnancy starting and ending between January 1, 2000, and December 31, 2010, were identified, who were aged 11-50 years at the start of pregnancy. Pregnancies were identified using algorithms previously developed and utilized at the University of Bath.^{5,13} The pregnancy start date was estimated based on medical codes in the woman's record; where information was not available, a defaulted pregnancy duration of 40 weeks for live and stillbirths and 10 weeks for pregnancy losses was used. The defaulted duration was used for approximately 40% of deliveries and 70% of pregnancy losses. Women were required to have had a singleton birth and have been followed in the CPRD for the 6 months before, throughout, and for at least 3 months after pregnancy. A more detailed description of the methods has been described previously.⁵

Women were considered to have asthma if they had:

- (a) an asthma diagnosis at any time in their medical record and 2 or more prescriptions for any asthma medicine during the study period or

- (b) 6 or more prescriptions for any asthma medicine during the study period

Asthma medicines included short-acting β_2 -agonists, ICS, LABA, compound bronchodilator preparations, cromoglycate and related therapy, leukotriene receptor antagonists, antimuscarinic bronchodilators, and theophylline products, and did not include the use of intranasal steroids. Women were required to receive 1 or more prescriptions during the 6 months before or during pregnancy. Women with a diagnosis of any other chronic respiratory disease were excluded.

For all asthma medicines, the duration of each prescription was calculated.⁵ In addition to those described above, oral corticosteroid prescriptions were identified where there was no evidence that they had been prescribed for a condition other than asthma. Each prescription was given a start and end date, and the prescriptions were mapped, taking into account the switching of products.⁵ Periods of long-term oral corticosteroid use (≥ 90 days) were included in the mapping, whereas short courses (< 90 days) were used to identify acute asthma exacerbations. The mapped prescription data were then used to determine the combination of products a patient was exposed to during each day of the study period.⁵

Women were assigned to treatment steps based on the combination of products prescribed and the British Thoracic Society and Scottish Intercollegiate Guidelines on the management of asthma.⁸ Women were only allocated to step 5 if long-term oral corticosteroid use was combined with a current prescription for high-dose ICS (> 800 μg for beclometasone dipropionate [BDP] or budesonide and > 400 μg for FP).


Each treatment step was assigned a value and an average treatment step value was calculated for each woman for the entire pregnancy, for each trimester, and for the 3 months before pregnancy as shown below.

$$\frac{\sum (\text{number of days on each treatment step} \times \text{step value})}{\text{total number of days in time period}}$$

Individuals were categorized into 1 of 3 "asthma treatment intensity levels" based on their average British Thoracic Society and Scottish Intercollegiate Guidelines treatment step value during each particular time period ("mild": $\leq$ step 1; "moderate": $>$ step 1 and $\leq$ step 2; "considerable to severe": $>$ step 2). The category "considerable to severe" included a wide range, with 51.2% classified as $>$ step 2 and $\leq$ step 3, 47.9% classified as $>$ step 3 and $\leq$ step 4, and the remainder being $>$ step 4 and $\leq$ step 5.

First trimester ICS exposure was defined as the issue of a prescription for any ICS during the first trimester or the 2 weeks preceding. FP exposure was categorized into "FP alone" (Flixotide), "FP in fixed-dose combination with salmeterol" (Seretide [FSC]) and "any FP." Women who received both "FP alone" and "FSC" were eligible for inclusion in both groups but only counted once in the "any FP" category. Women were included in the non-FP ICS category if they received a non-FP ICS prescription and no prescriptions for an FP product, regardless of the prescribing of any other asthma medicine classes. All exposure was determined masked to pregnancy outcome status.

For live deliveries, the mother's medical record, where possible, was linked to that of the infant; this was possible for approximately 80% of deliveries. MCMs were identified based on a Read code relating to an MCM in the infant's record. MCMs were defined according to the EUROCAT classification.^{14,15} In infants diagnosed with a syndrome, syndrome-related MCMs were excluded as these



* 54 women received a prescription for FP both as part of a fixed-dose combination and as an inhaler not part of a fixed-dose combination during the 1st trimester

FIGURE 1. Flow diagram of the asthma study cohort showing a breakdown of pregnancy outcome status and inhaled corticosteroid prescribing.

were unlikely to be drug induced, but any MCMs that were not reported in the literature as being part of that syndrome were included. Each potential MCM was verified using either supporting medical codes in the infant's record (eg, surgery code), free text comments, or by sending a questionnaire to the infant's GP. MCMs were identified in pregnancies that ended in a stillbirth or induced termination by requesting and reviewing free text comments recorded in association with a pregnancy-related medical code in the mother's record.

Analyses

The maternal patient characteristics were reported for all pregnancies where the woman received a prescription for an ICS, stratified by type of ICS. For pregnancies where the mother's medical record could be linked to that of the child or the pregnancy had ended in a pregnancy termination, the absolute risk of a pregnancy outcome with an MCM diagnosed by 1 year of age was calculated as shown below for each ICS exposure group, stratified by the first trimester asthma treatment intensity level.

Stillbirths and pregnancy losses without an MCM were excluded from the denominator because of the likelihood of

status, socioeconomic status, body mass index, change in asthma treatment step, oral corticosteroid use, and exacerbation occurrence. This was carried out separately for FP alone and FSC and also for the "any FP" category as there was no heterogeneity between exposure groups.

The primary outcome was an MCM diagnosed by 1 year of age because previous research had demonstrated that approximately only two-thirds of MCMs were recorded in an infant's medical record by 3 months of age. Sensitivity analyses were, however, carried out to evaluate the risks of an MCM diagnosed by 3 months of age and by 5 years of age to assess any impact on the risk estimates of loss to follow-up and to look at the impact of any malformations diagnosed later in life. Further sensitivity analyses were carried out by excluding MCMs where it was not possible to confirm or refute the diagnosis following the verification exercise. All analyses were carried out using Stata version 12.¹⁷ To investigate the impact of nonindependent pregnancies, where 1 woman contributed more than 1 pregnancy to the study cohort, sensitivity analyses were carried out for the primary outcome of interest (an MCM diagnosed by 1 year of age), which restricted the analyses to the first pregnancy of each woman.

The prevalence of MCM organ classes, identified in the different FP exposure groups, was calculated and compared with those reported by the UK contributing EUROCAT registries.¹⁸

RESULTS

In total, 25,247 pregnancies in 18,674 women with asthma were identified, of which 18,120 (71.8%) ended in a delivery. An ICS prescription had been issued during the first trimester in 10,770 pregnancies. Of these, 3,311 (30.7%) had received a prescription for FP, 807 for FP alone, and 2,558 for FSC (Figure 1). Non-FP ICS use consisted of BDP (approximately 80%), budesonide in a single inhaler (approximately 10%), and budesonide in a fixed-dose combination with the LABA formoterol (approximately 10%). The demographic patient characteristics of women prescribed FP during the first trimester were comparable with those prescribed a non-FP ICS (Table I). In general, women prescribed FSC did not differ from those prescribed FP alone on demographic features, although FSC users were more likely to be smokers ($P < .01$). With respect to differences in asthma, women receiving FP were more likely to be at the more severe end of the asthma treatment severity strata than women prescribed a non-FP ICS (Table I). Women prescribed FP were also more likely to have experienced an asthma exacerbation in the 6 months before pregnancy ($P < .01$) and to have

$$\frac{\text{No. of live deliveries with MCM} + \text{no. of stillbirths with MCM} + \text{no. of pregnancy losses with MCM}}{\text{Total no. of live deliveries} + \text{no. of stillbirths with MCM} + \text{no. of pregnancy losses with MCM}}$$

inconsistent identification of defects across these types of outcome; this approach is commonly taken by pregnancy registries.¹⁶ To be eligible for the analyses at 1 year of age infants had to still be registered in the CPRD at, or had died before, the time of their first birthday.

The relative risk of a pregnancy outcome with an MCM, diagnosed by 1 year of age, after first trimester exposure to FP compared with all non-FP ICS was calculated, stratified by the first trimester asthma treatment intensity level. Multivariate logistic regression was used to adjust for maternal age, alcohol consumption, smoking

received an oral corticosteroid prescription during the first trimester ($P < .01$) than those prescribed a non-FP ICS.

Within the asthma cohort, 14,654 mother-infant pairs were identified, of which 6,174 were exposed to an ICS during the first trimester and 5,912, 5,362, and 2,062 pregnancies were eligible for the primary and sensitivity analyses at 3 months, 1 year, and 5 years of age, respectively (Figure 2). A total of 622 potential MCMs in 514 pregnancies were identified (including 43 chromosomal defects and 35 syndrome related). Figure 3 shows the results of the verification exercise.

TABLE 1. Patient characteristics of women exposed to fluticasone propionate (FP) or another inhaled corticosteroid during the first trimester of pregnancy

Patient characteristic	Non-FP inhaled corticosteroids	FP alone (Flixotide)	FSC (Seretide)	Any FP product
	N (%)	N (%)	N (%)	N (%)
Number of pregnancy outcomes	7459	807	2558	3311
Mean age at LMP (y [SD])	29.4 [6.6]	29.9 [6.3]	29.7 [6.4]	29.7 [6.4]
Age at LMP (y)				
<20	669 (9.0)	42 (5.2)	178 (7.0)	217 (6.6)
20-24	1160 (15.6)	121 (15.0)	411 (16.1)	521 (15.7)
25-29	1779 (23.9)	210 (26.0)	631 (24.7)	834 (25.2)
30-34	2071 (27.8)	245 (30.4)	725 (28.3)	952 (28.8)
35-39	1369 (18.4)	138 (17.1)	470 (18.4)	600 (18.1)
40+	411 (5.5)	51 (6.3)	143 (5.6)	187 (5.7)
Smoking status				
Nonsmoker	3589 (48.1)	436 (54.0)	1199 (46.9)	1606 (48.5)
Current smoker	2390 (32.0)	211 (26.2)	801 (31.3)	997 (30.1)
Ex-smoker	1469 (19.7)	159 (19.7)	556 (21.7)	705 (21.3)
Unknown	11 (0.2)	1 (0.1)	2 (0.1)	3 (0.1)
Alcohol drinking status				
Teetotal	1020 (13.7)	127 (15.7)	362 (14.2)	480 (14.5)
Drinks alcohol	4969 (66.6)	548 (67.9)	1716 (67.1)	2229 (67.3)
Heavy drinker	129 (1.7)	10 (1.2)	44 (1.7)	54 (1.6)
Ex-drinker	352 (4.7)	24 (3.0)	124 (4.9)	145 (4.4)
Unknown	989 (13.3)	98 (12.1)	312 (12.2)	403 (12.2)
Body mass index (before LMP)				
<20	797 (10.7)	82 (10.2)	258 (10.1)	337 (10.2)
20-24	2680 (35.9)	280 (34.7)	933 (36.5)	1189 (35.9)
25-29	1656 (22.2)	198 (24.5)	600 (23.5)	789 (23.8)
30-34	823 (11.0)	89 (11.0)	286 (11.2)	366 (11.1)
>34	519 (7.0)	39 (4.8)	230 (9.0)	264 (8.0)
Unknown	984 (13.2)	119 (14.8)	251 (9.8)	366 (11.1)
Socioeconomic status (practice level)				
Quintile 1—least deprived	1257 (16.9)	152 (18.8)	480 (18.8)	624 (18.9)
Quintile 2	1399 (18.8)	199 (24.7)	436 (17.0)	621 (18.8)
Quintile 3	1450 (19.4)	122 (15.1)	481 (18.8)	593 (17.9)
Quintile 4	1595 (21.4)	146 (18.1)	489 (19.1)	628 (19.0)
Quintile 5—most deprived	1759 (23.6)	188 (23.3)	672 (26.3)	845 (25.5)
Pregnancy history*				
No. of previous deliveries				
0	3504 (47.0)	401 (49.7)	1146 (44.8)	1518 (45.8)
1	2484 (33.3)	287 (35.6)	881 (34.4)	1152 (34.8)
2	1027 (13.8)	92 (11.4)	376 (14.7)	461 (13.9)
>2	444 (6.0)	27 (3.3)	155 (6.1)	180 (5.4)
Previous preterm delivery	283 (3.8)	19 (2.4)	94 (3.7)	112 (3.4)
Previous spontaneous loss	1203 (16.1)	125 (15.5)	466 (18.2)	585 (17.7)
Asthma treatment intensity level				
Mild	162 (2.2)	10 (1.2)	12 (0.5)	22 (0.7)
Moderate	5139 (68.9)	274 (34.0)	350 (13.7)	623 (18.8)
Considerable to severe	2158 (28.9)	523 (64.8)	2196 (85.8)	2666 (80.5)
Change in average BTS treatment step†				
>1.0 decrease	141 (1.9)	41 (5.1)	145 (5.7)	186 (5.6)
>0.5 and ≤1.0 decrease	217 (2.9)	32 (4.0)	118 (4.6)	146 (4.4)
Remained the same	4967 (66.6)	514 (63.7)	1568 (61.3)	2050 (61.9)
>0.5 and ≤1.0 increase	1489 (20.0)	98 (12.1)	232 (9.1)	322 (9.7)
>1.0 increase	645 (8.6)	122 (15.1)	495 (19.4)	607 (18.3)

(continued)

TABLE I. (Continued)


Patient characteristic	Non-FP inhaled corticosteroids	FP alone (Flixotide)	FSC (Seretide)	Any FP product
	N (%)	N (%)	N (%)	N (%)
Asthma exacerbation in 6 mo before pregnancy				
Yes	754 (10.1)	155 (19.2)	505 (19.7)	638 (19.3)
No	6705 (89.9)	652 (80.8)	2053 (80.3)	2673 (80.7)
Prescription for an oral corticosteroid during the first trimester [‡]				
Yes	385 (5.2)	78 (9.7)	230 (9.0)	299 (9.0)
No	7074 (94.8)	729 (90.3)	2328 (91.0)	3012 (91.0)

BTS, British Thoracic Society; FSC, fluticasone propionate in fixed dose combination with salmeterol; LMP, last menstrual period.

*Recorded in the General Practice Research Database.

[†]Between the 3-mo period before pregnancy and the first trimester.

[‡]Either as part of a step 5 treatment regimen or issued for less than a 90-day duration in relation to the treatment of an exacerbation.



MCM = major congenital malformation

FIGURE 2. Flow diagram of the asthma study cohort showing the identification of pregnancies eligible for the congenital malformation analyses.

Of the 5,362 ICS exposed pregnancies eligible for the primary analysis at 1 year of age, 131 pregnancies were identified with an unrefuted MCM diagnosed by age 1 year (including MCMs where it was not possible to verify or refute the diagnosis and excluding chromosomal defects and defects part of a syndrome). There was no evidence of an increase in MCM risk for the offspring of women who received a prescription for FP during the first trimester compared with women who received a non-FP ICS product (Table II). In addition, no substantial differences were observed in those prescribed FP alone compared with those prescribed FSC. Restricting the analysis to only verified MCMs did not substantially change the risk estimates (see Table E1 in this article's Online Repository at www.jaci-inpractice.org).

No meaningful differences were observed when sensitivity analyses restricted MCMs to those diagnosed by 3 months of age (see Table E2 in this article's Online Repository at www.jaci-inpractice.org).




FIGURE 3. Verification of potential major congenital malformations.

When the analyses were restricted to MCMs diagnosed by 5 years, the absolute risks for FP exposed women were slightly higher than those prescribed a non-FP ICS. The differences observed, however, were not statistically significant and the number of exposures in some groups was low (Table E2). Restricting the primary analyses to the first pregnancy of each woman reduced the point estimates below the null for those with moderate asthma treatment intensity but did not substantially change the confidence intervals or the overall study findings (see Table E3 in this article's Online Repository at www.jaci-inpractice.org).

For all MCM subgroups, with the exception of the "urinary subgroup" in the non-FP ICS exposed group where the prevalence was higher, a comparison of the prevalence in the CPRD with data from UK contributing EUROCAT registries, restricted to the same study period, did not demonstrate any evidence of an increase in risk after ICS exposure (see Table E4 in this article's Online Repository at www.jaci-inpractice.org).

DISCUSSION

This study did not identify any increase in the overall risk of MCMs after exposure to FP during the first trimester of pregnancy compared with exposure to non-FP ICS. In addition, the

TABLE II. Risk of a pregnancy outcome with a major congenital malformation (MCM) diagnosed by 1 y of age for first trimester FP exposed pregnancies compared with all other non-FP ICS exposed pregnancies, stratified by the first trimester asthma treatment intensity level

	No. of exposed pregnancies*			
Asthma treatment intensity level and first trimester exposure type	N (%)†	No. of pregnancies with an MCM‡	Absolute risk of an MCM (95% CI)	Adjusted odds ratio§ (95% CI)
Mild				
Non-FP ICS	72 (1.2)	4	5.6 (0.3-10.8)	
FP alone (Flixotide)	7 (0.1)	0	0.0	
FSC (Seretide)	3 (0.0)	0	0.0	
Any FP exposure	10 (0.2)	0	0.0	
Moderate				
Non-FP ICS	2598 (64.1)	60	2.3 (1.7-2.9)	1
FP alone (Flixotide)	152 (3.8)	3	2.0 (0.0-4.2)	0.9 (0.3-2.9)
FSC (Seretide)	177 (4.4)	5	2.8 (0.4-5.3)	1.3 (0.5-3.2)
Any FP exposure	328 (8.1)	8	2.4 (0.8-4.1)	1.1 (0.5-2.3)
Considerable to severe				
Non-FP ICS	1080 (43.0)	25	2.3 (1.4-3.2)	1
FP alone (Flixotide)	273 (10.9)	8	2.9 (0.9-4.9)	1.3 (0.6-3.0)
FSC (Seretide)	1032 (41.1)	27	2.6 (1.6-3.6)	1.1 (0.6-2.0)
Any FP exposure	1274 (50.7)	34	2.7 (1.8-3.6)	1.2 (0.7-2.0)

FP, Fluticasone propionate; FSC, fluticasone propionate in fixed dose combination with salmeterol; ICS, inhaled corticosteroid.

*Ending in either a delivery or an induced termination of pregnancy after a prenatal MCM diagnosis.

†Percentage treated with this category of ICS within this asthma treatment intensity level.

‡Including MCMs where it was not possible to verify or refute the diagnosis.

§Adjusted for maternal age, socioeconomic status, and maternal smoking status.

risk of MCMs after the first trimester exposure to FP alone was not found to differ to the risk after exposure to FSC. To our knowledge, this is one of the first large population-based studies to evaluate the safety of FP when used during pregnancy in relation to the risk of MCMs and also to specifically evaluate the safety of an ICS delivered as part of a fixed-dose combination product with a LABA.

This study included more than 25,000 pregnant women with asthma, including more than 10,000 who received an ICS prescription during the first trimester. The prevalence of asthma and the frequency of asthma medicine prescribing in the GPRD has been demonstrated to be similar to that described elsewhere,⁵ which implies that the cohort is reasonably representative of the wider pregnant population with asthma.

Data on asthma medicines were recorded prospectively and independently by the prescriber, which prevented maternal recall bias. Exposure was, however, based on the issue of a prescription, and it was not possible to know whether it was dispensed and used, or used as directed with a proper inhaler technique. The nature of asthma and the high levels of poor treatment compliance will have resulted in some nondifferential exposure misclassification, and this would likely have resulted in a bias toward the null. Inclusion of prescriptions issued during the 2 weeks before the start of pregnancy will have helped to identify some, but not all, women who were exposed during the early stages of pregnancy but did not receive a prescription during the pregnancy itself. Misclassification of exposure may also have resulted from limitations in estimating the start of pregnancy and subsequently the precise timing of exposure. The lack of patient reported information (eg, Asthma Control Test) in electronic

medical databases is a limitation. Although this study attempted to take into account treatment intensity, the level of symptom control provided by a particular treatment regimen will vary between women. Within the CPRD, data on changes in symptom control that may not have been associated with a change in treatment regimen or required intervention with oral steroids were not available. Also, no information was available on medicines bought without a prescription, including 400 mcg folic acid, which is known to reduce the risk of some MCMs when taken during the periconception period.^{19,20}

This study identified a wide range of MCMs and had the strength of capturing prenatally diagnosed MCMs that resulted in an induced termination. It is possible that some MCMs may not have been recorded in a patient's record, but this is unlikely to be differential between exposure groups. This study, like the budesonide study,²¹ did however evaluate the risk of all MCMs combined, and it is recognized that this is usually insufficiently sensitive for detecting specific teratogenic associations. Although this study attempted to control for effects of varying "asthma severity," this measure was based on asthma treatment patterns and did not take into account treatment compliance or additional clinical asthma symptoms that are not routinely recorded in the CPRD. It is possible that this will have resulted in some confounding by indication that may not have been fully adjusted for in the stratified analyses and multivariate modeling.

This study compared FP exposure with exposure to all other non-FP ICS, and therefore one limitation is that if a class effect of an increased risk of MCMs associated with ICS exposure

exists, then this study design would not have been able to identify such a class effect. Given that treatment step guidelines recommend ICS as the backbone of persistent asthma maintenance therapy beginning in step 2, in an observational study design, it is not feasible to study a class effect without potential confounding by severity.

A small number of studies have reported on the first trimester ICS exposure and the risk of congenital malformations.²¹⁻²⁸ Many of these, however, have grouped all ICS products and have been limited by small numbers. Based on the studies available, there is general consensus that the use of ICS products during early pregnancy does not appear to be associated with an increased risk of congenital malformations overall when compared with either users of non-ICS asthma medicines^{23,25} or the general population.^{21,22} The findings of our study are in line with the published data. A recent study by Eltonsy et al compared the use of long-acting β_2 -agonists and inhaled corticosteroids in combination with higher dose inhaled corticosteroid monotherapy and found that the risk of MCMs was similar for the 2 groups.²⁹

Neither our study nor the Swedish study looked at ICS dose and its relationship with MCM risk. A study that used Canadian electronic health care data²⁴ has suggested that higher ICS dose (>1000 $\mu\text{g/day}$ BDP equivalent) may be associated with an increased risk of congenital malformations when compared with low and/or moderate doses (≤ 1000 $\mu\text{g/day}$). The adjusted odds ratios were 1.66 (CI₉₅ 1.02-2.68) and 1.67 (CI₉₅ 0.91-3.06) for all congenital malformations and MCMs, respectively, when high-dose ICS was compared with low and/or moderate doses. No increase in risk was observed when low and/or moderate exposures were compared with no ICS. The number of high-dose exposures was, however, small (N = 154), and it was not possible to rule out confounding by disease severity as a possible explanation for the observed increased risk.

CONCLUSION

In our population-based cohort study, FP users were at the more severe end of the asthma severity spectrum and therefore would be less likely to successfully discontinue their asthma medicines during pregnancy without the increased risk of asthma exacerbations and other symptoms. Our study found no evidence of an increased risk of MCMs after exposure to FP during the first trimester of pregnancy when compared with non-FP ICS. This is reassuring and in line with other studies that evaluate the safety of ICS products. This study had 90% power to detect a twofold increase in the risk of all MCMs diagnosed by 1 year of age but was not powered to detect smaller increases in risk. In addition to providing information on the safety profile of FP and other ICS, this study also in part evaluated the safety of the LABA salmeterol used in a fixed-dose combination with FP. Although FP exposures were mostly in combination with salmeterol in this study (77.9%) and the preliminary findings were reassuring, further data on the safety of LABA-containing regimens used during pregnancy are required to increase the precision of the risk estimates and further inform prescribers and patient decision making aiming to optimize asthma control during pregnancy.³⁰

Acknowledgment

Professor Corinne de Vries contributed substantively to the design of the study and development of the protocol while she was a member of the core study team at the University of Bath.

REFERENCES

1. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from National Health Surveys. *Ann Epidemiol* 2003;13:317-24.
2. Louik C, Schatz M, Hernández-Díaz S, Werler MM, Mitchell AA. Asthma in pregnancy and its pharmacologic treatment. *Ann Allergy Asthma Immunol* 2010;105:110-7.
3. Kurinczuk JJ, Parsons DE, Dawes V, Burton PR. The relationship between asthma and smoking during pregnancy. *Women Health* 1999;29:31-47.
4. Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. *Pharmacoepidemiol Drug Saf* 2010;19:408-17.
5. Charlton RA, Hutchison A, Davis KJ, de Vries CS. Asthma management in pregnancy. *PLoS One* 2013;8:e60247.
6. Murphy VE, Namazy JA, Powell H, Schatz M, Chambers C, Attia J, et al. A meta-analysis of adverse perinatal outcomes in women with asthma. *BJOG* 2011;118:1314-23.
7. Enriquez R, Griffin MR, Carroll KN, Wu P, Cooper WO, Gebretsadik T, et al. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. *J Allergy Clin Immunol* 2007;120:625-30.
8. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: A National Clinical Guideline; 2014. Available from: <http://www.sign.ac.uk/pdf/sign141.pdf>. Accessed June 4, 2015.
9. Medicines and Healthcare products Regulatory Authority. The Clinical Practice Research Datalink; 2013. Available from: <http://www.cprd.com>. Accessed November 13, 2013.
10. Margulis AV, Abou-Ali A, Strazzeri MM, Ding Y, Kuyateh F, Frimpong EY, et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. *Pharmacoepidemiol Drug Saf* 2013;22:942-51.
11. Charlton RA, Weil JG, Cunningham M, de Vries CS. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. *Drug Saf* 2011;34:157-71.
12. Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. *PLoS One* 2012;7:e51734.
13. Snowball JM, de Vries CS. Determination of pregnancy on the General Practice Research Database. *Pharmacoepidemiol Drug Saf* 2007;16:S118.
14. Dolk H. EUROCAT: 25 years of European surveillance of congenital anomalies. *Arch Dis Child Fetal Neonatal Ed* 2005;90:F355-8.
15. Eurocat. Minor Anomalies for Exclusion (Chapter 3.2, Guide 1.3); 2005. Available from: <http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf>. Accessed November 13, 2013.
16. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. *J Neurol Neurosurg Psychiatry* 2006;77:193-8.
17. StataCorp. Stata Statistical Software: Release 12. College Station, Tex: StataCorp LP; 2011.
18. EUROCAT. European Surveillance of Congenital Anomalies; 2013. Available from: <http://www.eurocat-network.eu/>. Accessed February 6, 2014.
19. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 1991;338:131-7.
20. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* 1992;327:1832-5.
21. Kallen B, Rydhstroekm H, Åberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. *Obstet Gynecol* 1999;93:392-5.
22. Tata LJ, Lewis SA, McKeever TM, Smith CJ, Doyle P, Smeeth L, et al. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study. *Thorax* 2008;63:981-7.

23. Kallen B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy: 3. Congenital malformations in the infants. *Eur J Clin Pharmacol* 2007;63:383-8.
24. Blais L, Beauchesne MF, Lemièrre C, Elftouh N. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. *J Allergy Clin Immunol* 2009;124:1229-34.
25. Blais L, Beauchesne MF, Rey E, Malo JL, Forget A. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. *Thorax* 2007;62:320-8.
26. Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. *Curr Med Res Opin* 2005;21:1075-84.
27. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review. *Hum Exp Toxicol* 2006;25:447-52.
28. Lin S, Munsie JP, Herdt-Losavio ML, Druschel CM, Campbell K, Browne ML, et al. Maternal asthma medication use and the risk of selected birth defects. *Pediatrics* 2012;129:e317-24.
29. Eltonsy S, Forget A, Beauchesne MF, Blais L. Risk of congenital malformations for asthmatic pregnant women using a long-acting β_2 -agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. *J Allergy Clin Immunol* 2015;135:123-30.
30. Eltonsy S, Forget A, Blais L. Beta2-agonists use during pregnancy and the risk of congenital malformations. *Birth Defects Res A Clin Mol Teratol* 2011;91:937-47.

TABLE E1. Risk of a pregnancy outcome with a major congenital malformation (MCM) diagnosed by 1 y of age for first trimester FP exposed pregnancies compared with all other non-FP ICS exposed pregnancies stratified by the first trimester asthma treatment intensity level restricted to MCMs that could be verified

Asthma treatment intensity level and first trimester exposure type	No. of exposed pregnancies*	No. of pregnancies with an MCM	Absolute risk of an MCM (95% CI)	Adjusted odds ratio‡ (95% CI)
	N (%)†			
Mild				
Non-FP ICS	72 (1.2)	4	5.6 (0.3-10.8)	
FP alone (Flixotide)	7 (0.1)	0	0.0	
FSC (Seretide)	3 (0.0)	0	0.0	
Any FP exposure	10 (0.2)	0	0.0	
Moderate				
Non-FP ICS	2598 (64.1)	56	2.2 (1.6-2.7)	1
FP alone (Flixotide)	152 (3.8)	3	2.0 (0.0-4.2)	0.9 (0.3-2.9)
FSC (Seretide)	177 (4.4)	5	2.8 (0.4-5.3)	1.3 (0.5-3.2)
Any FP exposure	328 (8.1)	8	2.4 (0.8-4.1)	1.1 (0.5-2.4)
Considerable to severe				
Non-FP ICS	1080 (43.0)	22	2.0 (1.2-2.9)	1
FP alone (Flixotide)	273 (10.9)	7	2.6 (0.7-4.4)	1.5 (0.6-3.4)
FSC (Seretide)	1032 (41.1)	26	2.5 (1.6-3.5)	1.2 (0.7-2.2)
Any FP exposure	1274 (50.7)	32	2.5 (1.7-3.4)	1.2 (0.7-2.1)

FP, Fluticasone propionate; FSC, fluticasone propionate in fixed dose combination with salmeterol; ICS, inhaled corticosteroid.

*Ending in either a delivery or an induced termination of pregnancy after a prenatal MCM diagnosis.

†Percentage treated with this category of ICS within this asthma treatment intensity level.

‡Adjusted for maternal age, socioeconomic status, and maternal smoking status.

TABLE E2. Risk of a pregnancy outcome with a major congenital malformation (MCM) for first trimester FP exposed pregnancies compared with all other non-FP ICS exposed pregnancies, stratified by the first trimester asthma treatment intensity level

Asthma treatment intensity level and first trimester exposure type	No. of exposed pregnancies*	No. of pregnancies with an MCM‡	Absolute risk of an MCM (95% CI)	Adjusted odds ratio§ (95% CI)
	N (%)†			
(a) Diagnosed by 3 mo of age				
Mild				
Non-FP ICS	82 (1.2)	3	3.7 (0.0-7.7)	
FP alone (Flixotide)	7 (0.1)	0	0.0	
FSC (Seretide)	3 (0.0)	0	0.0	
Any FP exposure	10 (0.1)	0	0.0	
Moderate				
Non-FP ICS	2868 (64.0)	47	1.6 (1.2-2.1)	1
FP alone (Flixotide)	159 (3.6)	3	1.9 (0.0-4.0)	1.2 (0.4-3.9)
FSC (Seretide)	203 (4.5)	5	2.5 (0.3-4.6)	1.6 (0.6-4.0)
Any FP exposure	361 (8.1)	8	2.2 (0.7-3.7)	1.4 (0.7-3.0)
Considerable to severe				
Non-FP ICS	1169 (42.2)	18	1.5 (0.8-2.2)	1
FP alone (Flixotide)	283 (10.2)	2	0.7 (0.0-1.7)	0.5 (0.1-2.1)
FSC (Seretide)	1171 (42.2)	24	2.1 (1.2-3.0)	1.3 (0.7-2.5)
Any FP exposure	1422 (51.2)	25	1.8 (1.1-2.4)	1.1 (0.6-2.1)
(b) Diagnosed by 5 y of age				
Mild				
Non-FP ICS	24 (1.1)	0	0.0	
FP alone (Flixotide)	4 (0.2)	0	0.0	
FSC (Seretide)	0 (0.0)	0	0.0	
Any FP exposure	4 (0.2)	0	0.0	
Moderate				
Non-FP ICS	1080 (67.1)	39	3.6 (2.5-4.7)	1
FP alone (Flixotide)	66 (4.1)	3	4.6 (0.0-9.6)	1.3 (0.4-4.4)
FSC (Seretide)	51 (3.2)	1	2.0 (0.0-5.8)	0.5 (0.1-3.9)
Any FP exposure	117 (7.3)	4	3.4 (0.1-6.7)	0.9 (0.3-2.7)
Considerable to severe				
Non-FP ICS	446 (49.4)	14	3.1 (1.5-4.8)	1
FP alone (Flixotide)	155 (17.2)	8	5.2 (1.7-8.6)	1.7 (0.7-4.3)
FSC (Seretide)	248 (27.5)	12	4.8 (2.2-7.5)	1.6 (0.7-3.5)
Any FP exposure	391 (43.3)	19	4.9 (2.7-7.0)	1.6 (0.8-3.3)

FP, Fluticasone propionate; FSC, fluticasone propionate in fixed dose combination with salmeterol; ICS, inhaled corticosteroid.

*Ending in either a delivery or an induced termination of pregnancy after a prenatal MCM diagnosis.

†Percentage treated with this category of ICS within this asthma treatment intensity level.

‡Including MCMs where it was not possible to verify or refute the diagnosis.

§Adjusted for maternal age, socioeconomic status, and maternal smoking status.

TABLE E3. Risk of a pregnancy outcome with a major congenital malformation (MCM) diagnosed by 1 y of age for first trimester FP exposed pregnancies compared with all other non-FP ICS exposed pregnancies, stratified by the first trimester asthma treatment intensity level—restricted to the first pregnancy for each woman (N = 3898—72.7% of the original cohort)

Control: restricted to the first pregnancy for each woman (N = 6666, 7.2% of the original cohort)					
Asthma treatment intensity level and first trimester exposure type	No. of exposed pregnancies*		No. of pregnancies with an MCM‡	Absolute risk of an MCM (95% CI)	Adjusted odds ratio§ (95% CI)
	N	(%)†			
Mild					
Non-FP ICS	51		2	3.9 (0.0-9.2)	
FP alone (Flixotide)	6		0	0	
FSC (Seretide)	2		0	0	
Any FP exposure	8		0	0	
Moderate					
Non-FP ICS	1974		46	2.3 (1.7-3.0)	1
FP alone (Flixotide)	117		2	1.7 (0.0-4.1)	0.8 (0.2-3.2)
FSC (Seretide)	128		2	1.6 (0.0-3.7)	0.7 (0.2-2.9)
Any FP exposure	244		4	1.6 (0.0-3.2)	0.7 (0.3-2.0)
Considerable to severe					
Non-FP ICS	764		17	2.2 (1.2-3.3)	1
FP alone (Flixotide)	206		7	3.4 (0.9-5.9)	1.7 (0.7-4.2)
FSC (Seretide)	677		18	2.7 (1.4-3.9)	1.2 (0.6-2.3)
Any FP exposure	857		24	2.8 (1.7-3.9)	1.3 (0.7-2.4)

FP, Fluticasone propionate; FSC, fluticasone propionate in fixed dose combination with salmeterol; ICS, inhaled corticosteroid.

*Ending in either a delivery or an induced termination of pregnancy after a prenatal MCM diagnosis.

†Percentage treated with this category of ICS within this asthma treatment intensity level.

‡Including MCMs where it was not possible to verify or refute the diagnosis.

§Adjusted for maternal age, socioeconomic status, and maternal smoking status.

TABLE E4. Prevalence of major congenital malformations diagnosed by 1 y of age stratified by first trimester inhaled corticosteroid exposure and grouped according to the EUROCAT criteria

Major congenital malformation	Non-FP inhaled corticosteroid (N = 3750)		FP alone (Flixotide) (N = 432)		FSC (Seretide) (N = 1212)	
	N*	(%)†	N*	(%)†	N*	(%)†
Nervous system	6	0.16 (0.03-0.29)	≤5	≤1.16 (0.15-2.17)	≤5	≤0.41 (0.05-0.77)
Eye	≤5	≤0.13 (0.02-0.25)	0		0	
Ear, face, and neck	0		0		0	
Congenital heart defects	(3) 27	0.72 (0.45-0.99)	≤5	≤1.16 (0.15-2.17)	13	1.07 (0.49-1.65)
Respiratory	0		0		0	
Orofacial clefts	≤5	≤0.13 (0.02-0.25)	0		≤5	≤0.41 (0.05-0.77)
Digestive system	(1) 7	0.21 (0.07-0.36)	≤5	≤1.16 (0.15-2.17)	≤5	≤0.41 (0.05-0.77)
Abdominal wall defects	≤5	≤0.13 (0.02-0.25)				
Urinary	(2) 20	0.59 (0.34-0.83)‡	0		6	0.50 (0.10-0.89)
Genital	6	0.16 (0.03-0.29)	≤5	≤1.16 (0.15-2.17)	≤5	≤0.41 (0.05-0.77)
Limb	(2) 18	0.53 (0.30-0.77)	≤5	≤1.16 (0.15-2.17)	6	0.50 (0.10-0.89)
Other anomalies/syndromes	(2) 4	0.16 (0.03-0.29)	(≤5)	≤1.16 (0.15-2.17)	(≤5) ≤5	<0.41 (0.05-0.77)
Teratogenic syndromes with malformations	≤5	≤0.13 (0.02-0.25)	0		(≤5)	<0.41 (0.05-0.77)
MCM type unknown—pregnancy ended in an induced termination	≤5	≤0.13 (0.02-0.25)	0		≤5	<0.41 (0.05-0.77)

FP, Fluticasone propionate; FSC, fluticasone propionate in fixed dose combination with salmeterol; MCMs, major congenital malformations

() = additional MCMs where it was not possible to confirm or refute the diagnosis.

*Reported as N ≤ 5 to ensure patient anonymity.

†Includes MCMs where it was not possible to confirm or refute the diagnosis.

‡Observed to be higher than the prevalence reported by EUROCAT and 95% confidence intervals for the 2 data sources did not overlap.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.